Biologics News

The Amedica Corporation recently released the results of its 24-month level 1 trial for the CASCADE composite silicon nitride fusion device, which has a central, cancellous ceramic core. The device provided similar fusion and NDI outcomes when compared with a PEEK and autograft device after spinal fusion procedures.

Investigators of this study recommend early detection and suitable treatment for primary bone lesions and conservative treatment for lung metastases and a regular long-term follow-up for patients with giant cell tumors of the bone.

Bioventus LLC has entered into a multi-year agreement with Institut Biochimique SA, a pharmaceutical company based in Switzerland, to secure the exclusive U.S. distribution rights for GELSYN-3.

Results from this level 1 study showed clinical outcomes, anatomic healing rate, and mean postoperative defect size and tendon quality at 1 year did not improve with the application of leucocyte- and platelet-rich fibrin during arthroscopic rotator cuff repair.

Use of microfracture and adipose-derived stem cells with fibrin glue showed improved radiologic and KOOS pain and symptom subscores in the treatment of symptomatic knee cartilage defects compared with the use of microfracture alone, according to results.

SpinalCyte LLC, a Texas-based tissue engineering company, recently announced it received a Chinese patent entitled, “Method of differentiating human dermal fibroblasts into chondrocyte-like cells using mechanical strain.”

In the January/February editorial of Orthopedics, Editor-in-Chief, Robert D. D’Ambrosia, MD, announced several changes being made to the print and online editions of the publication.

MiMedx Group Inc. recently announced it has completed the acquisition of Stability Biologics, a provider of human tissue products to surgeons and facilities. Under the deal, Stability Biologics will operate as a wholly owned subsidiary of MiMedx.

More variability in day-to-day pain and exacerbation of pain after daily physical activity was experienced among patients with osteoarthritis and certain genotypes for catechol-O-methyltransferase and mu-opioid receptor compared with patients who had other genotypes, according to results.

Researchers of this retrospective review found patients with adult spinal deformity who received bone morphogenetic protein-2 during their index spine surgery experienced a 7.5-fold decrease in the risk of reoperation for pseudarthrosis after long fusion.